Gain Therapeutics Announces Positive Results From the Single Ascending Dose (Sad) Part of the Phase 1 Clinical Trial of GT-02287, a Novel Gcase-Targeting Small Molecule Therapy for Gba1 Parkinson’s Disease
Gain Therapeutics 宣布 GT-02287(一种针对 Gba1 帕金森氏病的新型 Gcase 靶向小分子疗法)的 1 期临床试验的单一递增剂量(Sad)部分的阳性结果